PMID- 10584878
OWN - NLM
STAT- MEDLINE
DCOM- 19991214
LR  - 20181113
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 81
IP  - 7
DP  - 1999 Dec
TI  - Detection of circulating tumour cells in patients with breast or ovarian cancer 
      by molecular cytogenetics.
PG  - 1165-73
AB  - Detection of micrometastases in patients with solid tumours may aid the 
      establishment of prognosis and development of new therapeutic approaches. This 
      study was designed to investigate the presence and frequency of tumour cells in 
      the peripheral blood (PB) of patients with breast or ovarian cancer by using a 
      combination of magnetic activated cell sorting (MACS) and fluorescence in situ 
      hybridization (FISH). Separated tumour cell and PB-samples from 48 patients (35 
      breast cancers, 12 ovarian tumours, one uterine sarcoma) were analysed for the 
      presence of numerical aberrations of chromosomes 7, 12, 17 and 17 q11.2-q12. 
      Twenty-five patients had primary disease and 23 had relapsed. The technique 
      allows the detection of one tumour cell in 106 normal cells. Circulating tumour 
      cells were detected in 35/48 cases (17 patients had relapsed and 13 primary 
      carcinoma with lymph node or solid metastases) by the expression of 
      anti-cytokeratin and the presence of numerical chromosomal abnormalities. 
      PB-tumour cells of patients with a primary carcinoma and without solid metastases 
      had a significantly lower percentage of chromosomal aberrations, especially for 
      chromosome 12 (P = 0.035; P = 0.038) compared to those with relapsed disease and 
      solid metastases. Detection and quantification of minimal residual disease may 
      monitor the response to cytotoxic or hormonal therapy and may identify women at 
      risk of relapse.
FAU - Engel, H
AU  - Engel H
AD  - Department of Gynaecology and Obstetrics, University of Cologne, Germany.
FAU - Kleespies, C
AU  - Kleespies C
FAU - Friedrich, J
AU  - Friedrich J
FAU - Breidenbach, M
AU  - Breidenbach M
FAU - Kallenborn, A
AU  - Kallenborn A
FAU - Schondorf, T
AU  - Schondorf T
FAU - Kolhagen, H
AU  - Kolhagen H
FAU - Mallmann, P
AU  - Mallmann P
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Bone Marrow Cells/pathology
MH  - Breast Neoplasms/blood/genetics/*pathology
MH  - Cell Separation/methods
MH  - *Chromosome Aberrations
MH  - Cytogenetic Analysis
MH  - Female
MH  - Flow Cytometry
MH  - Follow-Up Studies
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Interphase/physiology
MH  - Magnetics
MH  - Middle Aged
MH  - Ovarian Neoplasms/blood/genetics/*pathology
MH  - Tumor Cells, Cultured
PMC - PMC2374326
EDAT- 1999/12/10 00:00
MHDA- 1999/12/10 00:01
CRDT- 1999/12/10 00:00
PHST- 1999/12/10 00:00 [pubmed]
PHST- 1999/12/10 00:01 [medline]
PHST- 1999/12/10 00:00 [entrez]
AID - 6690825 [pii]
AID - 10.1038/sj.bjc.6690825 [doi]
PST - ppublish
SO  - Br J Cancer. 1999 Dec;81(7):1165-73. doi: 10.1038/sj.bjc.6690825.